Metoprolol tartrate and succinate are two medications that are commonly prescribed to treat high blood pressure, angina, and other heart conditions. Both medications are beta blockers, meaning they work by blocking certain receptors in the body, which in turn lowers blood pressure and reduces the risk of heart attack and stroke. Despite their similar therapeutic effects, there are a few key differences between metoprolol tartrate and succinate. In this article, we will explore the differences between these two medications and discuss the pros and cons of each.
Metoprolol tartrate is a generic beta blocker that is used to treat high blood pressure, angina, and other heart conditions. It is a short-acting medication, meaning it starts to work quickly after taking it and the effects last for a short time. Metoprolol tartrate is usually taken once or twice a day, and it is available in both tablet and liquid form.
Metoprolol succinate is also a generic beta blocker, but it is a long-acting medication. This means that it takes longer to start working, but the effects last longer than with metoprolol tartrate. Metoprolol succinate is usually taken once a day and it is available in both tablet and extended-release tablet form.
When comparing metoprolol tartrate and succinate, there are a few key differences to consider. The first difference is the way the medications are absorbed into the body. Metoprolol tartrate is absorbed quickly, while metoprolol succinate is absorbed more slowly. This means that metoprolol tartrate starts working more quickly than metoprolol succinate, but the effects of metoprolol succinate last longer. Another difference between the two medications is the way they are metabolized in the body. Metoprolol tartrate is metabolized quickly, meaning it is broken down and eliminated from the body quickly. Metoprolol succinate is metabolized more slowly, meaning it stays in the body longer. This means that metoprolol tartrate needs to be taken more often than metoprolol succinate. The final difference between the two medications is the cost. Metoprolol tartrate is generally less expensive than metoprolol succinate, making it a more cost-effective option for many patients.
When deciding between metoprolol tartrate and succinate, it is important to consider the pros and cons of each medication. The main advantage of metoprolol tartrate is that it is a short-acting medication that starts working quickly. This makes it a good option for those who need to lower their blood pressure quickly or who need to take their medication more often. It is also generally less expensive than metoprolol succinate. The main advantage of metoprolol succinate is that it is a long-acting medication that stays in the body longer. This makes it a good option for those who need to take their medication less often or who need to maintain a lower blood pressure for a longer period of time.
Metoprolol tartrate and succinate are two medications that are commonly prescribed to treat high blood pressure, angina, and other heart conditions. Both medications are beta blockers, meaning they work by blocking certain receptors in the body, which in turn lowers blood pressure and reduces the risk of heart attack and stroke. Despite their similar therapeutic effects, there are a few key differences between metoprolol tartrate and succinate. Metoprolol tartrate is a short-acting medication that starts working quickly, while metoprolol succinate is a long-acting medication that stays in the body longer. Metoprolol tartrate is generally less expensive than metoprolol succinate, making it a more cost-effective option for many patients. When deciding between metoprolol tartrate and succinate, it is important to consider the pros and cons of each medication and to discuss the options with your doctor.
1.
Charles III, King of Kings, is Cancerous.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Ultimate Guide to Oncology Services in the USA
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation